logo

TLPH

Talphera·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

TLPH fundamentals

Talphera (TLPH) released its earnings on Nov 12, 2025: revenue was 1.00K (YoY 0.00%), beat estimates; EPS was -0.11 (YoY +15.38%), beat estimates.
Revenue / YoY
1.00K
0.00%
EPS / YoY
-0.11
+15.38%
Report date
Nov 12, 2025
TLPH Earnings Call Summary for Q3,2025
  • NEPHRO Study: Delays push completion to H1 2026; 2/6 new sites activated with similar enrollment rates.
  • FDA Process: Conditional approval for compassionate use in specific patient populations.
  • Capital: $21.3M cash, with sufficient funding through 2026.
  • Regulatory: Breakthrough designation maintains efficient engagement.
  • Commercial Readiness: Anticipated PMA approval in H2 2026.
EPS
Revenue

Revenue & Expenses

TLPH has released its 2025 Q3 earnings report, with revenue of 1.00K, reflecting a YoY change of NaN%, and net profit of -4.44M, showing a YoY change of -32.30%. The Sankey diagram below clearly presents TLPH's revenue sources and cost distribution.

Key Indicators

Talphera (TLPH) key financial stats and ratios, covering profitability, financial health, and leverage.
Talphera (TLPH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Talphera (TLPH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Talphera (TLPH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Talphera (TLPH) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Talphera (TLPH) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield